gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_Ctrl;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_Ctrl;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_Mut1;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_Mut1;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_Mut2;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_Mut2;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_Mut3;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_Mut3;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_WT1;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_WT1;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_WT2;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_WT2;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_WT3;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=293T_WT3;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV10001;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV10001;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1009;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1009;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1009;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1010;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1010;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1015;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1015;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1016;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1016;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1020;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1020;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1022;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1035;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1035;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1035;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1038;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1038;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1043;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1043;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1043;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1046;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1046;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1047;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1057;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1057;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1057;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1057;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1058;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1058;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1059;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1059;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1059;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1064;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1064;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1064;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1065;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1065;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1066;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1066;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1066;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1068;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1068;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1068;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1068;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1074;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1074;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1075;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1075;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1078;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1078;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1087;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1087;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1089;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1089;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1092;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1092;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1092;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1098;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1098;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1098;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1101;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1101;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1103;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1103;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1103;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1108;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1108;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1113;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1113;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1114;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1114;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1121;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1121;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1123;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1123;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1127;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1130;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1130;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1130;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1138;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1138;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1142;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1142;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1152;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1152;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1156;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1156;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1157;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1157;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1157;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1158;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1158;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1159;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1159;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1166;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1166;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1166;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1168;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1168;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1169;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1169;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1173;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1173;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1178;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1178;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1179;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1179;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1187;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1187;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1188;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1188;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1188;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1189;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1189;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1189;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV118;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV118;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV118;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV118;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1191;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1191;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1196;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1196;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1205;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1206;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1206;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1209;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1215;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1215;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1216;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1216;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1218;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1218;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV121;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV121;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1222;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1222;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1222;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1236;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1236;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1237;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1237;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1238;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1238;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1238;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1261;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1261;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1263;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1263;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1266;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1266;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1271;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1271;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1272;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1272;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1273;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1273;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1276;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1276;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1276;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1284;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1284;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1284;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1286;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1286;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1295;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1297;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV995;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV995;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=normal1;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=normal2;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=normal3;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=normal4;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=normal5;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=normal6;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1303;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1303;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1313;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1313;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1314;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1314;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1315;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1315;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1319;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1319;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1321;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1321;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1323;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1323;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1325;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1325;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1326;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1326;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1329;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1329;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1334;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1334;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1336;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1336;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1341;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1345;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1345;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1346;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1349;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1349;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1349;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1350;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1350;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1351;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1351;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1351;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1353;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1354;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1354;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1355;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1355;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1357;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1357;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1358;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1358;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1359;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1364;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1365;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1365;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1366;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1366;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1366;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1370;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1370;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1380;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1380;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1383;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1383;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1384;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1385;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1388;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1388;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1389;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1389;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1391;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1394;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1394;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1395;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1395;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1397;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1397;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1403;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1403;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1403;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1404;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1406;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1406;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1406;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1407;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1407;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1408;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1408;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1413;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1413;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1422;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1422;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1424;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1424;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1427;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1427;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1429;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1431;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1431;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1432;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1432;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1434;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1434;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1437;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1437;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1440;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1444;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1445;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1446;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1448;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1451;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1452;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1452;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1454;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1455;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1458;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1458;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1458;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1459;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1459;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV1460;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1464;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1464;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1470;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1470;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1473;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV1473;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1482;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1482;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV1482;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV175;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV175;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV177;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV177;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV19;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV19;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV19;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV200;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV200;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV219;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV219;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV219;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV219;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV219;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV221;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV221;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV225;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV225;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV242;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV242;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV242;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV244;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV244;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV244;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV259;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV259;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV259;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV298;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV298;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV350;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV350;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV359;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV359;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV366;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV366;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV366;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV38;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV38;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV415;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV415;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV417;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV417;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV448;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV448;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV448;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV481;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV481;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV481;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV482;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV482;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV492;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV492;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV492;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV492;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV554;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV554;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV559;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV559;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV584;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV584;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV584;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV586;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV586;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV587;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV587;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV588;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV588;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV593;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV593;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV593;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV598;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV598;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV603;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV603;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV603;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV605;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV605;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV607;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV607;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV609;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV609;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV609;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV609;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV618;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV618;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV623;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV628;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV628;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV628;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV628;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV631;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV631;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV631;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV636;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV641;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV641;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV642;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV642;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV642;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV642;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV642;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV647;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV647;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV649;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV649;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV656;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV656;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV658;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV658;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV663;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV663;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV663;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV664;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV664;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV674;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV674;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV676;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV676;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV679;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV679;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV680;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV680;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV683;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV683;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV689;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV689;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV692;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV692;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV693;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV693;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV695;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV695;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV698;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV698;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV698;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV698;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV698;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV699;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV699;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV701;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV701;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV701;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV701;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV734;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV734;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV734;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV756;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV756;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV776;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV776;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV830;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV836;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV836;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV838;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV838;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV859;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV859;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV859;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV865;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV865;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV866;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV866;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV868;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV868;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV868;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV869;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV869;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV869;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV870;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV870;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV870;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV872;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV872;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV872;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV873;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV873;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV875;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV875;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV881;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV881;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV886;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV886;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV889;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV889;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV898;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV898;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV906;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV906;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV908;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV908;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV910;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV910;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV912;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV912;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV912;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV913;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV913;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV915;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV915;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV916;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV916;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV918;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV918;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV921;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV921;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV922;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV922;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV926;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV926;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV926;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV926;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV927;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV928;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV928;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV929;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV929;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV929;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV929;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV932;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV932;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV934;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV934;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV934;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV934;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV937;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV937;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV951;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV951;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV952;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV952;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV954;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV954;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV957;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV965;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV965;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV970;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV970;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV971;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV971;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV974;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV974;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV974;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV97;ENA-CHECKLIST=ERC000026;
gender=unknown;phenotype=myeloid neoplasms;subject_id=PV97;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV982;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV982;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV983;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV983;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV990;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV990;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV991;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV991;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV993;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV993;ENA-CHECKLIST=ERC000026;
gender=female;phenotype=myeloid neoplasms;subject_id=PV993;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV995;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=myeloid neoplasms;subject_id=PV995;ENA-CHECKLIST=ERC000026;
